BOOST: a phase 3 trial of sorafenib vs. best supportive care in first line treatment of hepatocellular carcinoma in patients with deteriorated liver function
Gennaro Daniele(Università Cattolica del Sacro Cuore), Bruno Daniele(Azienda Ospedaliera G.Rummo), Stefano Tamberi(Azienda Unità Sanitaria Locale Della Romagna), Massimo Di Maïo(University of Siena), Claudia Mucciarini(Azienda Unita' Sanitaria Locale Di Modena), Angelo Dinota, Gino Crivellari(Istituto Oncologico Veneto), Ciro Gallo(University of Campania "Luigi Vanvitelli"), Laura Arenare(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Piera Federico, Raffaella Tortora, Clorinda Schettino(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Sandro Barni, Maria Carmela Piccirillo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Filippo Pelizzaro(University of Padua), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Domenico Bilancia(Azienda Ospedaliera Ospedale San Carlo Borromeo), Francesco Izzo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Francesco Perrone(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Luigi Bolondi(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Fabio Farinati(University of Padua), Luigi Cavanna(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Piera Gargiulo(Swiss Group For Clinical Cancer Research)
Cited by 5
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
|The Lancet Oncology|2015|1.1k
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.1k
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821